[1]甘　甜,郭志新,陈晓红.白脂素在2型糖尿病及其并发心脏、肾脏、视网膜病变中的作用研究进展[J].新乡医学院学报,2022,39(8):786-790.[doi:10.7683/xxyxyxb.2022.08.017]
　GAN Tian,GUO Zhixin,CHEN Xiaohong.Research progress on the role of asprosin in type 2 diabetes and its complications of heart,kidney disease and retinopathy[J].Journal of Xinxiang Medical University,2022,39(8):786-790.[doi:10.7683/xxyxyxb.2022.08.017]
点击复制

白脂素在2型糖尿病及其并发心脏、肾脏、视网膜病变中的作用研究进展
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
39
期数:
2022年8
页码:
786-790
栏目:
综述
出版日期:
2022-08-05

文章信息/Info

Title:
Research progress on the role of asprosin in type 2 diabetes and its complications of heart,kidney disease and retinopathy
作者:
甘　甜1; 郭志新2; 陈晓红1
(1.山西医科大学第二临床医学院，山西　太原　030001；2.山西医科大学第二医院内分泌科，山西　太原　030009)
Author(s):
GAN Tian1; GUO Zhixin2; CHEN Xiaohong1
(1.The Second Clinical Medical College of Shanxi Medical University,Taiyuan 030001,Shanxi Province,China;2.Department of Endocrinology,the Second Hospital of Shanxi Medical University,Taiyuan 030009,Shanxi Province,China）
关键词:
2型糖尿病; 并发症; 发病机制; 白脂素
Keywords:
type 2 diabetes; complication; pathogenesis; asprosin
分类号:
R587.1
DOI:
10.7683/xxyxyxb.2022.08.017
文献标志码:
A
摘要:
2型糖尿病为糖尿病的最主要类型,约占糖尿病的90%。2型糖尿病易出现多种慢性并发症，导致器官功能障碍和衰竭，致残、致死率高，是严重威胁人类健康的主要疾病之一。白脂素是一种新发现的脂肪因子，具有调节血糖作用，与胰岛素抵抗、肥胖等糖尿病的危险因素相关；白脂素在糖尿病及其慢性并发症的发生、发展中起一定作用，可能成为2型糖尿病诊断和治疗的新靶点。本文就白脂素在2型糖尿病及其并发心脏、肾脏和视网膜病变中的作用研究进展进行综述，旨在为研究早期诊断糖尿病及其并发症的预测性生物化学指标提供新的方向。
Abstract:
Type 2 diabetes is the most important type of diabetes,accounting for 90% of diabetes.Type 2 diabetes is prone to a variety of chronic complications,leading to organ dysfunction and failure,and it has high disability and mortality,so it is one of the major diseases which seriously threaten human health.Asprosin is a newly discovered adipokine,which has the effect of regulating blood glucose,and it is related to the risk factors of diabetes such as insulin resistance and obesity.Asprosin plays a certain role in the occurrence and development of diabetes and its chronic complications,and it may be a new target for the diagnosis and treatment of type 2 diabetes.This paper reviews the research progress of the role of asprosin in type 2 diabetes and its associated heart,kidney disease and retinopathy,in order to provide a new direction for the study of predictive biochemical indicators for the early diagnosis of diabetes and its complications.

参考文献/References:

［1］　ROMERE C,DUERRSCHMID C,BOURNAT J,et al.Asprosin,a fasting-induced glucogenic protein hormone［J］.Cell,2016,165(3):566-579.
［2］　GOZEL N,KILINC F.Investigation of plasma asprosin and saliva levels in newly diagnosed type 2 diabetes mellitus patients treated with metformin［J］.Endokrynol Pol,2021,72(1):37-43.
［3］　GOODARZI G,SETAYESH L,FADAEI R,et al.Circulating levels of asprosin and its association with insulin resistance and renal function in patients with type 2 diabetes mellitus and diabetic nephropathy［J］.Mol Biol Rep,2021,48(7):5443-5450.
［4］　ZHANG H Y,HU W Q,ZHANG G.Circulating asprosin levels are increased in patients with type 2 diabetes and associated with early-stage diabetic kidney disease［J］.Int Urol Nephrol,2020,52(8):1517-1522.
［5］　VALAIYAPATHI B,GOWER B,ASHRAF A P.Pathophysiology of type 2 diabetes in children and adolescents［J］.Curr Diabetes Rev,2020,16(3):220-229.
［6］　POLYZOS S A,KOUNTOURAS J,MANTZOROS C S.Obesity and nonalcoholic fatty liver disease:from pathophysiology to therapeutics［J］.Metabolism,2019,92:82-97.
［7］　SHETTY S S,KUMARI S.Fatty acids and their role in type-2 diabetes(review)［J］.Exp Ther Med,2021,22(1):706.
［8］　UGUR K,AYDIN S.Saliva and blood asprosin hormone concentration associated with obesity［J］.Int J Endocrinol,2019,2019:2521096.
［9］　WANG M,YIN C,WANG L,et al.Serum asprosin concentrations are increased and associated with insulin resistance in children with obesity［J］.Ann Nutr Metab,2019,75(4):205-212.
［10］　ZHANG X,JIANG H,MA X,et al.Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus［J］.J Diabetes Investig,2020,11(2):349-355.
［11］　胡芬,张运峰.Fc-Asprosin融合蛋白表达及糖尿病患者血清Asprosin水平检测［J］.基因组学与应用生物学,2018,37(8):3647-3651.
HU F,ZHANG Y F.Fc-Asprosin fusion protein expression and detection of serum Asprosin levels in diabetic patients［J］.Gen Appl Biol,2018,37(8):3647-3651.
［12］　NAIEMIAN S,NAEEMIPOUR M,ZAREI M,et al.Serum concentration of asprosin in new-onset type 2 diabetes［J］.Diabetol Metab Syndr,2020,12:65.
［13］　DUERRSCHMID C,HE Y,WANG C,et al.Asprosin is a centrally acting orexigenic hormone［J］.Nat Med,2017,23(12):1444-1453.
［14］　BEUTLER L R,KNIGHT Z A.A spotlight on appetite［J］.Neuron,2018,97(4):739-741.
［15］　NACKIEWICZ D,DAN M,HE W,et al.TLR2/6 and TLR4-activated macrophages contribute to islet inflammation and impair beta cell insulin gene expression via IL-1 and IL-6［J］.Diabetologia,2014,57(8):1645-1654.
［16］　CAI K,QI D,WANG O,et al.TNF-α acutely upregulates amylin expression in murine pancreatic beta cells［J］.Diabetologia,2011,54(3):617-626.
［17］　JAISWAL N,GAVIN M G,QUINN W J,et al.The role of skeletal muscle Akt in the regulation of muscle mass and glucose homeostasis［J］.Mol Metab,2019,28:1-13.
［18］　JUNG T W,KIM H C,KIM H U,et al.Asprosin attenuates insulin signaling pathway through PKCδ-activated ER stress and inflammation in skeletal muscle［J］.J Cell Physiol,2019,234(11):20888-20899.
［19］　LEE T,YUN S,JEONG J H,et al.Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation［J］.Mol Cell Endocrinol,2019,486:96-104.
［20］　LV J C,ZHANG L X.Prevalence and burden of chronic kidney disease［J］.Adv Exp Med Biol,2019,1165:3-15.
［21］　JIANG G Z,LUK A O Y,TAM C H T,et al.Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with type 2 diabetes［J］.Kidney Int,2019,95(1):178-187.
［22］　黄显元,刘建红,朱彦儒.α-硫辛酸对糖尿病肾病自噬相关因子LC3、Rab7和Beclin1表达的影响［J］.中国免疫学杂志,2019,35(17):2073-2078.
HUANG X Y,LIU J H,ZHU Y R.Effect of α-lipoic acid on the expression of autophagy related factors LC3,Rab7 and Beclin1 in diabetic nephropathy［J］.Chin J Immunol,2019,35(17):2073-2078.
［23］　WANG R,HU W.Asprosin promotes β-cell apoptosis by inhibiting the autophagy of β-cell via AMPK-mTOR pathway［J］.J Cell Physiol,2021,236(1):215-221.
［24］　ZHANG H,HU W,ZHANG G.Circulating asprosin levels are increased in patients with type 2 diabetes and associated with early-stage diabetic kidney disease［J］.Int Urol Nephrol,2020,52(8):1517-1522.
［25］　DENG X,ZHAO L,GUO C,et al.Higher serum asprosin level is associated with urinary albumin excretion and renal function in type 2 diabetes［J］.Diabetes Metab Syndr Obes,2020,13:4341-4351.
［26］　KATTAWY H,ASHOUR W.Anti-asprosin:a potential protective role against the progression of diabetic nephropathy in type 2 diabetic rats［J］.Am J Biomed Sci,2019,11(3):183-199.
［27］　YUAN M,LI W,ZHU Y,et al.Asprosin:a novel player in metabolic diseases［J］.Front Endocrinol(Lausanne),2020,11:64.
［28］　SEVERINO P,AMATO A D,PUCCI M,et al.Ischemic heart disease pathophysiology paradigms overview:from plaque activation to microvascular dysfunction［J］.Int J Mol Sci,2020，21(21):8118.
［29］　HE Y M,SHEN L,GE J B.Fallacies and possible remedies of the SYNTAX score［J］.J Interv Cardiol,2020,2020:8822308.
［30］　ACARA A C,BOLATKALE M,KIZILO GˇLU I,et al.A novel biochemical marker for predicting the severity of ACS with unstable angina pectoris:asprosin［J］.Am J Emerg Med,2018,36(8):1504-1505.
［31］　YU S P,WEI Z,WEI L.Preconditioning strategy in stem cell transplantation therapy［J］.Transl Stroke Res,2013,4(1):76-88.
［32］　ZHANG Z,TAN Y,ZHU L,et al.Asprosin improves the survival of mesenchymal stromal cells in myocardial infarction by inhibiting apoptosis via the activated ERK1/2-SOD2 pathway［J］.Life Sci,2019,231:116554.
［33］　赵越.代谢综合征合并冠心病患者血清Asprosin水平及其与代谢指标的相关性研究［D］.镇江：江苏大学,2019.
ZHAO Y.Serum asprosin level in patients with metabolic syndrome and coronary heart disease and its correlation with metabolic［D］.Zhenjiang:Jiangsu University,2019.
［34］　FENG J,YANG Y X,YANG Y J,et al.GW29-e0080 The protective role of asprosin against diabetes in cardiomyocytes［J］.Am Coll Cardiol,2018,72(Suppl):C2.
［35］　陈莎,汪雄,邱琛茗,等.Spartin和白脂素在糖尿病心脏微血管内皮损伤中的作用及其机制探讨［J］.四川大学学报(医学版),2019,50(6):827-834.
CHEN S,WANG X,QIU C M,et al.Study of the role and mechanism of asprosin/spartin pathway in cardiac microvascular endothelial injury by diabete mellitus［J］.J Sichuan Univ(Med Sci Edi),2019,50(6):827-834.
［36］　冯健,杜劲,侯娟妮,等.白脂素对高糖导致的心肌细胞损伤保护作用的研究［J］.中国糖尿病杂志,2018,26(9):775-779.
FENG J,DU J,HOU J N,et al.Protective effect of asprosin on the high glucose-induced apoptosis incardiomyocytes［J］.Chin J Diabetes,2018,26(9):775-779.
［37］　WEN M S,WANG C Y,YEH J K,et al.The role of asprosin in patients with dilated cardiomyopathy［J］.BMC Cardiovasc Disord,2020,20(1):402.
［38］　ROTHSCHILD P S,ALLEN P L,HOOSHMAND J,et al.Intravitreal anti-VEGF agents and cardiovascular risk:comment［J］.Intern Emerg Med,2021,16(2)533-536.
［39］　ORUC Y,CELIK F,OZGUR G,et al.Altered blood and aqueous humor levels of asprosin,4-hydroxy-deoxyguanosine in patients with diabetes mellitus and cataract with and without diabetic retinopathy［J］.Retina,2020,40(12):2410-2416.
［40］　黄庆先,胡文超,何兰杰.血清asprosin与糖尿病视网膜病变的相关性研究［J］.国际内分泌代谢杂志,2020,40(6):372-375.
HUANG Q X,HU W C,HE L J.Association of serum asprosin concentrations with diabetic retinopathy［J］.Int J Endocrinol Metab,2020,40(6):372-375.

相似文献/References:

[1]石建中,刘金萍,张桂梅.改良Madigan 前列腺切除术及其并发症的防治[J].新乡医学院学报,2000,17(06):431.
[2]孙　毅,王文菊,吴铭辉,等.小儿急性白血病强化疗后并发症的综合防治与护理[J].新乡医学院学报,2000,17(06):474.
[3]李伟华 刘芝建 常虹.巨大儿122例分析[J].新乡医学院学报,2000,17(04):269.
[4]杨延芳,刘　朝,宫晓红.青光眼手术并发脉络膜上腔出血(附2 例报告)[J].新乡医学院学报,2000,17(05):387.
[5]刘坤中,叶蔚.急性心肌梗塞的机械并发症及处理[J].新乡医学院学报,2000,17(01):066.
[6]孔秋艳.呼吸道异物372例手术并发症分析[J].新乡医学院学报,2001,18(05):353.
[7]张高富.腹部创伤早期再手术2O例分析[J].新乡医学院学报,2002,19(06):492.
[8]翁孝刚.2型糖尿病与胰岛B一细胞功能[J].新乡医学院学报,2002,19(03):231.
[9]张红旭,安运卿,王 斌,等.老年肝炎肝硬化95例回顾性分析[J].新乡医学院学报,2002,19(03):198.
[10]周振华,苏国强,张保峰.开腹胆囊切除术和腹腔镜胆囊切除术并发症的比较[J].新乡医学院学报,2002,19(04):301.

更新日期/Last Update: 2022-08-05